Corbus Pharmaceuticals reported Phase 1b obesity data for its CB1 inverse agonist, arguing that its mechanism may reduce neuropsychiatric side effects seen with earlier CB1-targeting efforts. The company said it plans to start Phase 2 after additional evidence of tolerability and the obesity signal. In a parallel competitive readout across the broader obesity landscape, the GLP-1 category continues to reshape expectations for weight-loss pipelines and downstream real-world access. Market focus is increasingly split between injectable GLP-1s and next-generation mechanistic variations, with companies positioning around differentiation in safety, efficacy, and persistence.